Maven Securities’s BioAtla BCAB Stock Holding History

Maven Securities’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-164	Closed	-$285K	–	1169
2020 Q4	$285K	Buy	+164	New	+$274K	0.03%	429

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Maven Securities's BCAB Position: Q1 2021 in Review

Maven Securities sold out of BioAtla (BCAB) in Q1 2021, closing a stake of 164 shares — an estimated $285K sold.

Maven Securities first reported a position in BCAB in Q4 2020 and held it in 1 quarter. The position peaked at $285K in Q4 2020. 62 funds tracked by Wall St. Rank hold BCAB as of Q1 2021.

Maven Securities reported no remaining BioAtla position as of Q1 2021 after selling out during the quarter.
Maven Securities sold 164 BioAtla shares in Q1 2021, an estimated $285K.
Maven Securities first reported a position in BioAtla in Q4 2020 and held it in 1 quarter.
Maven Securities's BioAtla position peaked at $285K in Q4 2020.
62 funds tracked by Wall St. Rank held BioAtla as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.